Daily Respiratory Research Analysis
Three impactful respiratory-focused studies stood out today: a translational nanomedicine study showed GMP-scale selenium nanoparticles boost chemo-immunotherapy efficacy in advanced NSCLC via selenoprotein-driven NK activation; a large randomized trial found delayed cord clamping in elective cesarean late preterm/early term births is safe but does not reduce early neonatal respiratory disease; and a multi-cohort analysis linked low CC16 with Mycoplasma pneumoniae seropositivity to lower FEV1 in
Summary
Three impactful respiratory-focused studies stood out today: a translational nanomedicine study showed GMP-scale selenium nanoparticles boost chemo-immunotherapy efficacy in advanced NSCLC via selenoprotein-driven NK activation; a large randomized trial found delayed cord clamping in elective cesarean late preterm/early term births is safe but does not reduce early neonatal respiratory disease; and a multi-cohort analysis linked low CC16 with Mycoplasma pneumoniae seropositivity to lower FEV1 in asthma, highlighting epithelial/host–pathogen biomarker interplay.
Research Themes
- Translational nanomedicine enhancing lung cancer chemo-immunotherapy
- Perinatal respiratory outcomes and delivery practices (delayed cord clamping)
- Airway epithelial biomarkers (CC16) and infection history impacting lung function in asthma
Selected Articles
1. Translational Selenium Nanoparticles Promotes Clinical Non-small-cell Lung Cancer Chemotherapy via Activating Selenoprotein-driven Immune Manipulation.
This translational study links selenium deficiency to immune dysfunction in advanced NSCLC, scales GMP production of selenium nanoparticles (SeNPs) to 500 L, and demonstrates that SeNPs activate GPX–mTOR signaling to expand NK cells and boost cytotoxicity. In an investigator-initiated clinical combination with bevacizumab/cisplatin/pemetrexed, SeNPs achieved an 83.3% objective response and 100% disease control, suggesting a selenoprotein-driven immunometabolic augment of chemo-immunotherapy.
Impact: It provides a clinically translational nanomedicine with mechanistic clarity and GMP scalability, showing high response rates when combined with standard first-line NSCLC therapy.
Clinical Implications: If validated in randomized trials, SeNP supplementation could be integrated with first-line chemo-immunotherapy to enhance NK-driven antitumor responses in advanced NSCLC; monitoring selenium status may inform patient selection.
Key Findings
- GMP-level 500-L production of selenium nanoparticles was achieved for clinical translation.
- SeNPs activated GPX–mTOR signaling, expanding NK cells and enhancing cytotoxicity against tumor cells.
- In an investigator-initiated clinical combination regimen (bevacizumab/cisplatin/pemetrexed), SeNPs yielded ORR 83.3% and DCR 100%.
Methodological Strengths
- Mechanistic validation across in vitro, in vivo, and clinical settings with GMP-scale manufacturing
- Clear immune pathway linkage (GPXs–mTOR) explaining NK-mediated antitumor effects
Limitations
- Non-randomized investigator-initiated clinical study with unspecified sample size limits causal inference
- Long-term safety, durability of response, and generalizability remain to be established
Future Directions: Conduct multicenter randomized controlled trials to confirm efficacy and safety; define biomarkers (selenium status, selenoprotein/GPX activity, NK functional readouts) for patient selection; evaluate combinations with checkpoint inhibitors.
Reconstructing the tumor immune microenvironment is an effective strategy to enhance therapeutic efficacy limited by immunosuppression in non-small-cell lung cancer (NSCLC). In this study, it is found that selenium (Se) depletion and immune dysfunction are present in patients with advanced NSCLC compared with healthy volunteers. Surprisingly, Se deficiency resulted in decreased immunity and accelerated rapid tumor growth in the mice model, which further reveals that the correlation between micronutrient Se and lung cancer progression. This pioneering work achieves 500-L scale production of Se nanoparticles (SeNPs) at GMP level and utilizes it to reveal how and why the trace element Se can enhance clinical immune-mediated treatment efficacy against NSCLC. The results found that translational SeNPs can promote the proliferation of NK cells and enhance its cytotoxicity against cancer cells by activating mTOR signaling pathway driven by GPXs to regulate the secretion of cytokines to achieve an antitumor response. Moreover, a clinical study of an Investigator-initiated Trial shows that translational SeNPs supplementation in combination with bevacizumab/cisplatin/pemetrexed exhibits enhanced therapeutic efficacy with an objective response rate of 83.3% and a disease control rate of 100%, through potentiating selenoprotein-driven antitumor immunity. Taken together, this study, for the first time, highlights the translational SeNPs-enhanced therapeutic efficacy against clinical advanced NSCLC.
2. Impact of delayed cord clamping on respiratory distress in late preterm and early term infants in elective cesarean section: a single centre, phase Ⅲ, randomised controlled trial.
In a large single-center phase III RCT of elective cesarean late preterm and early term infants, delayed cord clamping was safe but did not reduce early neonatal respiratory disease compared with immediate clamping (aRR 0.93, 95% CI 0.75–1.14). Maternal and neonatal adverse events were similar between groups.
Impact: High-quality randomized evidence addresses a common perinatal intervention and clarifies that DCC, while safe, does not lower early respiratory morbidity in this population.
Clinical Implications: For elective cesarean late preterm and early term deliveries, DCC can be offered for hematologic benefits without expecting reductions in early respiratory disease; neonatal respiratory risk mitigation should focus on other strategies.
Key Findings
- NRD incidence was 8.4% with delayed cord clamping vs 9.5% with immediate clamping (aRR 0.93; 95% CI 0.75–1.14).
- No significant differences in maternal or neonatal adverse events (e.g., Apgar <7, hypothermia, hypoglycemia, maternal hemorrhage, transfusion).
- Large randomized cohort: 1,418 neonates (DCC) vs 1,419 (ICC), mean GA 37.9 weeks.
Methodological Strengths
- Phase III randomized controlled design with large sample size and prespecified outcomes
- Comprehensive safety assessment for both mothers and infants
Limitations
- Single-center, open-label design may limit generalizability and introduce performance bias
- Trial focused on elective cesarean late preterm/early term population; findings may not generalize to vaginal or emergency deliveries
Future Directions: Evaluate DCC effects stratified by anesthesia type and neonatal risk profile; investigate adjunct perinatal respiratory support strategies beyond DCC in elective cesarean births.
BACKGROUND: Delayed cord clamping (DCC) has the potential to alleviate respiratory distress by augmenting blood volume and oxygenation, although there is currently a lack of direct evidence to support this. Late preterm and early term infants born via elective cesarean section (CS) are known to be more vulnerable to the neonatal respiratory distress (NRD). This study was designed to examine the effect of DCC on NRD of these infants. METHODS: Conducted from January 1, 2019 to January 31, 2024 at Shanghai First Maternity and Infant Hospital, this single-centre, phase Ⅲ, open-label randomised controlled trial included newborns delivered via elective CS between 34 FINDINGS: Of 2610 randomised women, 1418 neonates were included in the DCC group and 1419 in the ICC group. The mean maternal age for both groups was 33 (4) years, and all mothers were of Han ethnicity. The mean gestational age of the neonates was 37.9 (0.9) weeks in both groups. NRD occurred in 119 (8.4%) in DCC versus 135 (9.5%) in ICC (Adjusted Relative Risk [aRR] 0.93, 95% CI 0.75-1.14). There were no significant differences in infant and maternal adverse events such as low Apgar score (aRR 0.74, 95% CI 0.25-2.19), hypothermia (aRR 1.00, 95% CI 0.89-1.12), hypoglycemia (aRR 1.04, 95% CI 0.77-1.38), maternal intrapartum massive bleeding (aRR 0.96, 95% CI 0.76-1.19), or the requirement for transfusion (aRR 0.34, 95% CI 0.10-1.15). INTERPRETATION: Delayed cord clamping was safe for both mothers and infants in late preterm and early term delivered by elective cesarean section, while it did not reduce the risk of early respiratory diseases. FUNDING: This trial was funded by Shanghai Municipal Health Commission, China in 2019 (201940140) and National Natural Science Foundation of China in 2022 (82204047).
3. Circulating CC16, immune response to Mycoplasma pneumoniae and lung function: a population-based, multi-cohort study.
Across BAMSE, MAAS, LSC, and TESAOD cohorts, low circulating CC16 was linked to lower lung function overall, and asthmatics with both low CC16 and Mp IgG positivity exhibited markedly reduced FEV1% predicted. The data suggest epithelial integrity/protection (CC16) and prior Mp exposure jointly identify a higher-risk asthma subgroup.
Impact: Integrates biomarker biology with infection history across multiple cohorts to refine asthma risk stratification for airflow limitation.
Clinical Implications: CC16 measurement, combined with Mp serostatus, could help identify asthmatics at risk of lower FEV1 who may benefit from closer monitoring, epithelial-protective strategies, and infection prevention.
Key Findings
- Low circulating CC16 was associated with reduced lung function in the overall adult population across cohorts.
- Among asthmatics, the low CC16/Mp IgG positive group had markedly lower FEV1% predicted compared with other strata.
- No combined CC16–Mp effects were seen in the total population, highlighting a disease-specific interaction in asthma.
Methodological Strengths
- Population-based, multi-cohort design spanning BAMSE, MAAS, LSC, and TESAOD with harmonized biomarker stratification
- Objective serology (Mp IgG) and biomarker (CC16) measurements linked to spirometry
Limitations
- Observational, cross-sectional analyses limit causal inference and temporality
- Potential residual confounding and variability in cohort-specific protocols
Future Directions: Prospective studies to test whether CC16 restoration or epithelial-protective therapies mitigate FEV1 decline; evaluate Mp vaccination or infection prevention strategies in low-CC16 asthma phenotypes.
BACKGROUND: Sufficient levels of club cell secretory protein (CC16) are essential to protect against lung function impairments. Experimental studies have demonstrated that CC16 modulates inflammatory responses and protects against airway hyperresponsiveness following Mycoplasma pneumoniae (Mp) infection. Individuals with asthma have low CC16 levels and increased susceptibility to Mp infection. Here we determine whether low CC16 and Mp seropositivity have combined effects on lung function deficits predisposing to airflow limitation, particularly in asthma. METHODS: Serum levels of CC16 and IgG antibodies against Mp (MpIgG) were measured in adult participants from cohorts BAMSE, MAAS, LSC, and TESAOD. Participants were then stratified into four groups: normal CC16/MpIgG-, normal CC16/MpIgG+, low CC16/MpIgG-, low CC16/MpIgG+. Associations between these groups and lung function (FEV RESULTS: Low CC16 was associated with decreased lung function in the total population, but no combined effects of CC16 and MpIgG were observed. Among asthmatic participants, the low CC16/MpIgG + group had remarkably lower FEV CONCLUSION: This suggests that individuals with asthma with low levels of CC16 combined with a history of Mp infection may be more susceptible to deficits in FEV